Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
about
α-Keto phenylamides as P1'-extended proteasome inhibitorsDesensitization: Overcoming the Immunologic Barriers to TransplantationInhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathwayMisfolded proteins: from little villains to little helpers in the fight against cancer.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo.Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome systemA reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cellsEvaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsMechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Axonal Transport Impairment in Chemotherapy-Induced Peripheral NeuropathyNatural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive AgentsIn Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.Positioning of proteasome inhibitors in therapy of solid malignancies.Variabines A and B: new β-carboline alkaloids from the marine sponge Luffariella variabilis.
P2860
Q27694709-2EEFFEAE-3FF6-4463-AC97-48F36CB9CCA8Q30397952-767FEFD6-05D8-4F33-9F4A-F89676C9A327Q34455663-E974EB58-FCAA-45E7-8A8C-A47DBA082933Q34466592-CF276E68-074C-4CCF-A661-F25A4DBDA127Q34788381-04C1AE9F-3570-4963-8B67-08F9B927EF24Q35856827-027D87E7-5DC6-46F7-BABB-189DFFDFE04AQ36413676-ED91F2E0-5FB0-4EED-8DE8-775B356FE590Q36414426-1409EEE0-F3B7-4106-B0ED-5E672D9AB11BQ37015742-64FCF19A-3685-4931-8C31-C826D8810F93Q38181445-BE8AE971-E85A-4855-A310-9C9FD68F42E2Q38444221-1CB7E03A-C8E0-473D-94FF-FBE1E6793FB8Q39043749-E9679236-353E-4636-88E3-9FDF61EE57F5Q39084493-E22889F7-C09B-40EF-A6B8-6AA663AC7230Q39139112-616F326D-74CA-43FA-80ED-74DD1987A692Q39234159-F0B0104B-EF58-43E7-85A0-E31B9CC7AEE8Q41620033-516AA42B-6806-4D00-91A6-11CF0518104FQ41770950-247A4FA0-BF75-44FD-BB60-7A1588AFA59EQ42361415-4C5A1080-AF0D-42AA-9F9E-253CE0102B2EQ42755952-B79CE127-6780-48CB-8656-CFE8AE398D0EQ46379792-57C5B807-5743-4216-91D6-6C6914C994D8Q46667078-C92148A1-9465-42DD-9EB9-101CB71C8048Q47353792-E78AA3A1-8D3C-43E9-86C8-AC0E229BDCF9Q50981919-AABCFDB3-2058-442E-BC13-D7BE3022A38C
P2860
Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@ast
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@en
type
label
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@ast
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@en
prefLabel
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@ast
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@en
P2860
P356
P1476
Carfilzomib: a second-generati ...... d refractory multiple myeloma.
@en
P2093
Jennifer L Thompson
P2860
P356
10.1345/APH.1R561
P407
P577
2013-01-08T00:00:00Z